Abstract A wide variety of herbal remedies are used in traditional African medicine to treat rheumatoid arthritis (RA) and inflammation. Thirty-four extracts from 13 South African plant species with a history of ethnobotanical usage in the treatment of inflammation were investigated for their ability to control two microbial triggers for RA (Proteus mirabilis and Proteus vulgaris). Twenty-nine of the extracts (85.3 %) inhibited the growth of P. mirabilis and 23 of them tested (67.7 %) inhibited the growth of P. vulgaris. Methanol and water extracts of Carpobrotus edulis, Lippia javanica, Pelargonium viridflorum, Ptaeroxylon obliquum, Syzygium cordatum leaf and bark, Terminalia pruinoides, Terminalia sericea, Warburgia salutaris bark and an aqueous extract of W. salutaris leaf were effective Proteus inhibitors, with MIC values \2,000 lg/ml. The most potent extracts were examined by Reverse phase high performance liquid chromatography and UV-Vis spectroscopy for the presence of resveratrol. Only extracts from T. pruinoides and T. sericea contained resveratrol, indicating that it was not responsible for the anti-Proteus properties reported here. All extracts with Proteus inhibitory activity were also either non-toxic, or of low toxicity in the Artemia nauplii bioassay. The low toxicity of these extracts and their inhibitory bioactivity against Proteus spp. indicate their potential for blocking the onset of rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the joints which afflicts approximately 0.5-1 % of the world's population, with approximately three times as many women affected as men (Lawrence et al. 1998 ). Onset generally occurs in middle to old age, although younger individuals may also be affected. The disorder is characterised by inflammation of the synovial membranes of the joints, causing the joint to become swollen, hot and painful and reducing its mobility. The disease may produce only mild to moderate symptoms in some individuals. In many sufferers, it produces severe, disabling pain and a substantial loss of function and mobility if not adequately treated. There is currently no known cure for RA and current treatment strategies aim to either alleviate the symptoms (particularly pain and swelling) with analgesics and anti-inflammatory agents, and/or to somehow modify the disease process through the use of disease modifying anti-rheumatic drugs (DMARDs) . None of these current treatments is ideal as prolonged usage of these drugs is often accompanied by unwanted side effects and toxicity (Alataha et al. 2003) . There is still a need to find and develop safer, more effective drugs for the treatment of RA which will not only alleviate the symptoms, but may also cure or prevent the disease. A greater understanding of the disease's onset and progression could assist in more relevant drug discoveries and treatment options. Previous publications have already discussed the possibility of treating early phases of the diseases progression, particularly by removing the trigger (Whitehouse et al. 2013) .
The causes of RA are currently not well understood. It is generally accepted to be an autoimmune disorder which may be triggered by specific microbial infections in genetically susceptible individuals (individuals with the MHC class 2 allele HLA-DR4) (Nepom et al. 1989 ). There has been much conjecture as to the nature of the arthritogenic infection(s) and several bacterial (Ebringer and Rashid 2006; Auger et al. 1996; Holoshitz et al. 1986 ) and viral (Alvarez-Lafuente et al. 2005) agents have been proposed. The roles of most of these in the pathogenic mechanisms that lead to RA have not been conclusively demonstrated, many being ruled out as causative agents because of the contradictory evidence. Indeed, the only bacteria whose link with RA has not been conclusively disproven are those with the Proteus species (especially Proteus mirabilis) infections. Many studies have documented the presence of elevated serum levels of antibodies specific to Proteus mirabilis in individuals suffering from RA (Rashid et al. 1999; Blankenberg-Sprenkels et al. 1998; Chou et al. 1998; Subair et al. 1995; Wanchu et al. 1997; Senior et al. 1995) . Furthermore, Proteus mirabilis infections have been consistently reported in urine samples from patients with RA (Senior et al. 1999) .
The involvement of Proteus species as a RA trigger has also been confirmed by immunological experiments which demonstrated that sera from rabbits immunised with HLA-DR4 positive lymphocytes would bind to Proteus but not to any of the other 18 microbial species tested (Ebringer et al. 1985) . Furthermore, amino acid sequence homologies have been identified between the 'EQ/KRRAA' motif present in RA HLA-susceptibility antigens and the 'ESRRAL' amino acid sequence present in P. mirabilis haemolysins (Ebringer et al. 1992) . A further homology between the 'LRREI' sequence of type XI collagen (present in joint cartilage) and the 'IRRET' motif present in the urease enzyme from various Proteus species has also been reported (Wilson et al. 1995) .
Proteus mirabilis is present in soil and water and also is part of the normal flora of the human gastrointestinal tract. It is not pathogenic in most individuals. It is only when it enters the urinary tract or the bloodstream that it seems to become pathogenic and stimulates an immune response (Coker et al. 2000) . It has been postulated that Proteus infections (particularly in the urinary tract) induce the production of anti-ESRAAL and anti-IRRET antibodies and these antibodies are cross-reactive with tissues containing EQ/KRRA or LRREI peptide sequences, particularly hyaline cartilage in the joints of the hands and feet (Ebringer and Rashid 2006) . This antibody binding activates a number of downstream processes including inflammatory cascades involving acute phase proteins, components of the complement cascade, vasoactive amines, as well as cytokines, tumour necrosis factor-a (TNF-a) and various other cytotoxic components (Firestein 2003; Choy and Panayi 2001) . Furthermore, this antibody's cross-reactivity activates further cellular processes, including those involving the action of natural killer cells. These events subsequently result in the development of Proteus reactive RA. Initial infections often result in mild symptoms. Recurrent infections result in enhanced production of cross-reactive antibodies and intensification of the immunological reactions with resulting tissue damage.
Based on the evidence linking Proteus bacterial infections with pathogenesis, several lines of research are aimed at the treatment and management of RA by targeting the bacteria itself. One strategy is the development of antiProteus vaccines. Whilst the production of a vaccine may block proliferation of the Proteus species, it is also a problematic approach as anti-Proteus antibodies could also cross-react with the host's connective tissue in susceptible individuals, thus exacerbating the symptoms of RA. If antibodies lacking cross-reactive epitopes are developed in the future, this approach may be effective as it would enable susceptible individuals to resist some consequences of a Proteus infection. However, the development and usage of Proteus-sensitive antibiotics may prove a more effective means of blocking RA initiation/progression. Destroying the Proteus bacteria would be expected to greatly reduce the impact of the bacteria on inflammation, diminish the production of anti-Proteus antibodies and thus decrease disease progression.
Many antibiotics are already known to inhibit Proteus growth; however, the development of super-resistant bacterial strains has reduced their value for treating many bacterial infections (Wang et al. 2009; Liaw et al. 2001 ). The search is ongoing for new antimicrobials, either by (a) the design and synthesis of new agents, or (b) re-searching the repertoire of natural resources for as yet unrecognised or poorly characterised antimicrobial agents. The antiseptic qualities of medicinal plants have been long recognised by many cultures. Recently, there has been a revival of interest in herbal medications due to perceptions that there is often a lower incidence of adverse reactions to natural phytochemicals compared to synthetic pharmaceuticals.
In this study, some Southern African plants were identified which have been traditionally used for the treatment of RA as well as other inflammatory disorders (Table 1) . Relevant plant species were selected and the extracts tested against two Proteus species (P. mirabilis and P. vulgaris) to assess their potential to block their proliferation. Several of these plant species previously identified as having antiinflammatory properties have also been extensively studied for their antiseptic properties against other bacteria. For example, the antibacterial activity of Terminalia sericea against a wide panel of bacteria has been well documented (Steenkamp et al. 2007; Moshi and Mbwambo 2005) . Similarly, Syzygium cordatum has broad-spectrum antimicrobial activity (Sibandze et al. 2010; Steenkamp et al. 2007 ). However, we were unable to locate many published studies reporting any activities of these plants against Proteus species. Only Kigelia africana bark extract (Jeyachandran and Mahesh 2007) and Agathosma betulina extracts (Vermaak et al. 2009; Sandasi 2008) have been shown to have inhibitory activity against P. vulgaris. No further studies were found examining the ability of the extracts of these plants to inhibit the growth of P. mirabilis, which is more commonly associated with RA. Several other plant species examined in this study are closely related taxonomically with species of known anti-Proteus activity. Ballota africana has not been examined for antiProteus activity despite its ethnobotanical uses (Table 1 ), yet the ability of compounds isolated from the related species Ballota nigra has been shown to strongly inhibit P. mirabilis growth (Didry et al. 1999) . Some other species examined in this study (e.g. Pentanisia prunelloides, Ptaeroxylon obliquum) have not been carefully examined for their antimicrobial properties despite their long history of treatment for rheumatism.
Materials and methods

Ethnobotanical information
Several literature resources (Table 1) were utilised to identify Southern African plants with a history of usage in the treatment of rheumatism and other inflammatory disorders.
Plant collection and extraction
The majority of the plant species tested in this study were collected from the Walter Sisulu Botanical Gardens in Johannesburg, South Africa (SA). Lippia javanica was collected in situ from Fairlands (north of Johannesburg). Syzygium cordatum was obtained from Maputaland (KwaZulu-Natal, SA) and Agathosma betulina was collected from Landmeterskop (Southern Cape, SA). All plants were identified by Andrew Hankey, chief botanist at the Walter Sisulu Botanical Gardens in Johannesburg, SA or respective authorities in the other provinces. Voucher specimens were prepared and are stored at the Department of Pharmacy and Pharmacology, University of Witwatersrand, Johannesburg, SA. All plant materials were air dried and ground into a fine powder.
One gram of each dried plant material was weighed into each of two tubes. Extracts were prepared by adding either 50 ml of AR grade methanol or 50 ml distilled water to the tubes. Plant material was extracted in each solvent for 24 h at 4°C with gentle shaking. The extracts were filtered through filter paper (Whatman No. 54) . The methanol extracts were subsequently allowed to dry at room temperature. The aqueous extracts were frozen at -70°C and dried by lyophilisation. These dried extracts were then weighed and redissolved in 10 ml deionised water.
Antibacterial screening
Test microorganisms
Reference strains of Proteus mirabilis (ATCC 43071) and Proteus vulgaris (ATCC 33420) were obtained from American Tissue Culture Collection (ATCC). Both species were subcultured and maintained in nutrient broth (Oxoid Ltd, UK) at 4°C.
Evaluation of antimicrobial activity
Antimicrobial activity of all plant extracts was determined using a modified disc diffusion method (Cock and Mohanty 2011; Cock 2009 ). Briefly, 100 ll of the test bacteria was grown in 10 ml of fresh nutrient broth until they reached a count of approximately 10 8 cells/ml. One hundred microlitres of this microbial suspension was spread onto nutrient agar plates.
The extracts were tested using 5 mm sterilised filter paper discs impregnated with 10 ll of the test sample, then allowed to dry and placed onto inoculated plates. The plates were allowed to stand at 4°C for 2 h, allowing for prediffusion of the extract into the agar before incubation with the test microbial agents. The plates were incubated at 30°C for 24 h, then the diameters of the inhibition zones were measured in millimetres. All measurements were to the closest whole millimetre. Each antimicrobial assay was performed at least in triplicate and mean values were determined. Standard discs of ampicillin (2 lg) and chloramphenicol (10 lg) were obtained from Oxoid Ltd, UK and served as positive controls for antimicrobial activity. Filter discs impregnated with either 10 ll of distilled water or methanol were used as negative controls.
Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentrations (MIC) of the plant extracts were determined by the disc diffusion MIC method (Cock and Kukkonen 2011; Vesoul and Cock 2011) across Anti-Proteus activity of some South African medicinal plants 25 
Toxicity screening
Reference toxin for biological screening Potassium dichromate (K 2 Cr 2 O 7 ) (AR grade, Saarchem, South Africa) was prepared as a 1.6 mg/ml solution in distilled water and serially diluted in artificial seawater for use in the Artemia franciscana nauplii bioassay.
Artemia franciscana (brine shrimp) nauplii toxicity screening Toxicity was tested using a modified Artemia franciscana nauplii lethality assay Cock 2008, 2010; Cock 2008) . A. franciscana cysts were obtained from North American Brine Shrimp, LLC, USA (harvested from the Great Salt Lake, Utah). Artificial seawater was prepared using Reef Salt, AZOO Co., USA. Seawater solutions at 34 g/l distilled water were prepared prior to use. An amount of 2 g of A. franciscana cysts were incubated in 1 L synthetic seawater under artificial light at 25°C, 2000 Lux with continuous aeration. Hatching commenced within 16-18 h of incubation. Newly hatched A. franciscana (nauplii) were used within 10 h of hatching. Nauplii were separated from the shells and remaining cysts and concentrated to a suitable density by placing an artificial light at one end of their incubation vessel. The nauplii-rich water closest to the light was removed for viability assays. 400 ll of seawater containing approximately 37 (mean = 37.2, n = 132, SD = 11.6) nauplii was added to wells within a 48 well plate and immediately used for the bioassay. The plant extracts were first diluted to 4 mg/ml in seawater and then used at a 2 mg/ml concentration in the bioassay. A volume of 400 ll of diluted plant extract and the reference toxin was transferred to the wells and incubated at 25 ± 1°C under artificial light (1,000 Lux). A negative control (400 ll seawater) was included in triplicate for each plate. All treatments were performed in at least triplicate. The wells were checked at regular intervals and the number of dead brine shrimp counted. The nauplii were considered moribund if no movement of the appendages was observed within 10 s. After 72 h all nauplii were killed (by the addition of 50 ll glacial acetic acid) and counted to determine the total number per well. The LC 50 with 95 % confidence limits for each treatment was calculated using Probit analysis.
Reverse phase high performance liquid chromatography (RP-HPLC)
Gradient RP-HPLC was performed at a flow rate of 1 mg/ml using a Dionex Ultimate 3000 pump and gradient system, an Ultimate 3000 variable wavelength programmable photodiode array detector (Dionex) and a Phenomenex reverse phase C 18 column (150 mm 9 4.6 mm). The HPLC system was equipped with Chromeleon software (Dionex). The gradient was constructed as follows: 5 min elution with 5 % acetonitrile, followed by a 30-min gradient to 65 % acetonitrile. The system was then re-equilibrated to 5 % acetonitrile for subsequent chromatograms. The column temperature was maintained at 20°C throughout. Plant extract samples (10 ll) were injected manually. Resveratrol (Sigma) was dissolved in ethanol (AR grade), diluted in deionised water and 10 ll aliquots of various concentrations were injected as a standard to calibrate the HPLC column. 10 ll of deionised water was used as a negative control to produce the baseline curve and zero the equipment prior to each experiment.
Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments.
Results
Liquid extraction yields
Extraction of 1 g of the dried plant materials with methanol and water yielded dried plant extracts ranging from 6 mg (W. salutaris bark water extract) to 284 mg (P. obliquum leaf methanolic extract) ( Table 2) . No general trend was evident with regard to which solvent was more efficient at extracting material from the plant samples. Methanol extracted a greater amount of material for 7 of the 16 plant samples tested (43.8 %), whereas water extracted the greater amount of material for 8 of the 16 plant samples (50 %). One source provided equal masses of extract with both water and methanol. No obvious correlation was noted between the plant part tested and the amount of extracted material. For two plant species (Syzygium cordatum and Warburgia salutaris), both bark and leaf materials were extracted. Approximately five times as much material was extracted from Syzygium cordatum bark than from the leaves by methanol. Similarly, water extracted twice as much material from the bark than from the leaves. In contrast, much more material was extracted from Warburgia salutaris leaves than from the bark by both methanol and water (approximately eightfold and twofold higher, respectively). With another plant (Tulbaghia violaceae), leaf and root materials were extracted and tested. Methanol extracted significantly more material from Tulbaghia violaceae leaves than from the roots. However, water extracted much more material from Tulbaghia violaceae roots than from the leaves. All dried extracts were resuspended in 10 ml of deionised water, yielding the concentrations shown in Table 2 .
Antibacterial activity
Decoctions and tinctures are the main forms in which these plants are traditionally used in ethnobotanical medicinal systems. Therefore, methanolic and aqueous extracts were tested undiluted to provide an approximate measure of the efficacy of the form in which the traditional medications would be used. Aliquots (10 ll) of each extract were screened against P. mirabilis (Fig. 1a) and P. vulgaris (Fig. 1b) . P. mirabilis was susceptible to inhibition by a wider range of plant extracts than was P. vulgaris. Indeed, the only plant material for which neither the methanol or water extracts inhibited P. mirabilis growth was the T. violaceae root extracts. P. mirabilis was inhibited by 29 of the 34 (85.3 %) extracts tested compared to 23 of the 34 (67.7 %) extracts tested for P. vulgaris. P. vulgaris was susceptible to neither the methanol nor the water extracts of S. cordatum bark and leaf extracts, K. africana leaf extracts, P. fasiculata leaf extracts and T. violaceae root extracts. Zones of inhibition[10 mm were considered to indicate significant antimicrobial activity (Fig. 1) . The most effective inhibitors of P. mirabilis growth were the water extracts of Terminalia sericea and Terminalia pruinoides based on the zones of inhibition (17.3 ± 0.6 and 15.7 ± 0.6 mm, respectively). Indeed, these extracts displayed more potent P. mirabilis growth inhibition than either of the control antibiotics (ampicillin and chloramphenicol). The T. sericea and T. pruinoides methanol extracts also strongly inhibited P. mirabilis growth, albeit with smaller zones of inhibition (14.7 ± 0.6 and 11.0 ± 1.0 mm, respectively) than seen with the water extracts. The S. cordatum bark methanol (13.0 ± 1.0 mm) and water (13.7 ± 0.6 mm) extracts, S. cordatum leaf methanol (10.0 ± 1.0 mm) and water (13.0 ± 0 mm) extracts, C. edulis leaf methanol (11.0 ± 1.0 mm) and water (11.7 ± 0.6 mm) extracts, K. africana water extract (10.7 ± 0.6 mm), L. javanica methanol extract (11.7 ± 0.6 mm) and the P. fasicilata leaf methanol (10.7 ± 0.3 mm) and water (11.3 ± 0.6 mm) extracts all displayed strong inhibitory activity against P. mirabilis and thus were considered the most promising.
The T. sericea and T. pruinoides methanol extracts (15.7 ± 0.6 and 12.7 ± 0.6 mm, respectively) and water extracts (15.0 ± 0 and 14.7 ± 0.6 mm, respectively) were similarly effective against P. vulgaris. The S. cordatum bark methanol (13.3 ± 0.6 mm) and water (12.3 ± 0.6 mm) extracts, S. cordatum leaf methanol (10.7 ± 0.6 mm) and water (12.7 ± 0.6 mm) extracts, and the L. javannica methanol extract (15.3 ± 0.6 mm) also displayed strong inhibitory activity ([10 mm) against P. vulgaris and thus were considered the most promising.
The relative level of antibacterial activity was further quantified by determining the MIC values for each extract against the bacterial species which were shown to be susceptible by disc diffusion assays. In general, the MIC values against P. mirabilis were substantially lower than against P. vulgaris, with one notable exception (P. viridflorum leaf methanol extract). The T. sericea leaf methanol and water extracts, T. pruinoides leaf methanol and water extracts, S. cordatum bark methanol and water extracts, S. cordatum leaf methanol and water extracts, C. edulis leaf methanol and water extracts and the L. javanica leaf methanol extract were again the most effective antibacterial agents against both bacterial species, with MIC values generally below 1,000 lg/ml. S. cordatum leaf water extract was the most effective anti-P. mirabilis agent, with a MIC of 49 lg/ml. Although still an effective growth inhibitor of P. vulgaris, this extract displayed a higher MIC value of 658 lg/ml.
Quantification of toxicity
The plant extracts were serially diluted in artificial seawater for toxicity testing in the Artemia nauplii lethality bioassay. For comparison, the reference toxin potassium dichromate was also tested in the bioassay. Figure 2a , b shows the % mortality induced in the Artemia nauplii following 24 and 48 h of exposure, respectively. Potassium dichromate (reference toxin) rapidly induced of mortality within the first 3 h of exposure (results not shown). After 24 h exposure, potassium dichromate had killed all of the Artemia nauplii. At 24 h, the only extracts to induce mortality significantly above that of the seawater control were the P. fasiculata leaf water extract, T. violaceae root water extract and the T. violaceae leaf water extract. Although the levels of mortality had increased for most extracts after 48 h exposure (notably for the L. javanica leaf methanolic extract and the W. salutaris bark methanolic extract), the % mortality was still below 50 % and thus these extracts were considered of low toxicity (Table 3) .
To compare the toxicity of those plant extracts showing significant mortality with other toxins, the LC 50 values of the extracts were determined by testing across the concentration range 2,000-125 lg/ml in the Artemia nauplii bioassay. For comparison, potassium dichromate was tested across the same concentration range. Table 4 shows the Fig. 2 The lethality of plant extracts (2,000 lg/mL) and potassium dichromate control (1,000 lg/mL) towards Artemia nauplii after a 24 h and b 48 h exposure. All bioassays were performed in triplicate and the mean ±SEM are shown here. 1 A. betulina leaf methanolic extract; 2 A. betulina leaf water extract; 3 B. africana leaf methanolic extract; 4 B. africana leaf water extract; 5 C. edulis leaf methanolic extract; 6 C. edulis leaf water extract; 7 K. africana leaf methanolic extract; 8 K. africana leaf methanolic extract; 9 L. javanica leaf methanolic extract; 10 L. javanica leaf water extract; 11 P. fasiculata leaf methanolic extract; 12 P. fasiculata leaf water extract; 13 P. viridiflorum leaf methanolic extract; 14 P. viridiflorum leaf water extract; 15 P. obliquum leaf methanolic extract; 16 P. obliquum leaf water extract; 17 S. cordatum bark methanolic extract; 18 S. cordatum bark water extract; 19 S. cordatum leaf methanolic extract; 20 S. cordatum leaf water extract; 21 T. pruinoides leaf methanolic extract; 22 T. pruinoides leaf water extract; 23 T. sericea leaf methanolic extract; 24 T. sericea leaf water extract; 25 T. violaceae root methanolic extract; 26 T. violaceae root water extract; 27 T. violaceae leaf methanolic extract; 28 T. violaceae leaf water extract; 29 W. salutaris bark methanolic extract; 30 W. salutaris bark water extract; 31 W. salutaris leaf methanolic extract; 32 W. salutaris leaf water extract; 33 potassium dichromate control; 34 deionised water control Anti-Proteus activity of some South African medicinal plants 31
LC 50 values of the extracts which had shown toxicity towards A. franciscana. Whilst the P. fasiculata leaf water extract initially appeared toxic in the extract mortality screening study (Fig. 2) , determination of its LC 50 demonstrates that it is non-toxic as LC 50 values of C1,000 lg/ ml have previously been defined as non-toxic in the Artemia nauplii bioassay (Meyer et al. 1982 ). The T. violaceae root and leaf water extracts displayed 24 h LC 50 values of approximately 800 lg/ml which is considered to be low in toxicity. At 48 h, both the T. violaceae root and leaf water extracts showed slightly higher (although still low) toxicity, both with 48 h LC 50 values of approximately 700 lg/ ml. In contrast, potassium dichromate (the positive control) displayed substantially higher toxicity at 24 h (24 h LC 50 92 lg/ml) and 48 h (48 h LC 50 85 lg/ml).
RP-HPLC analysis of extracts displaying antimicrobial activity
The Proteus growth inhibition and MIC studies indicated that the L. javanica leaf, S. cordatum bark, S. cordatum leaf, T. pruinoides leaf and T. sericea leaf extracts were the most promising extracts for further phytochemical characterisation. These were examined for the presence of the phytochemical trans-3,4,5-trihydroxy-trans-stilbene (resveratrol). Resveratrol is a potent phenolic antiinflammatory antioxidant produced as a phytoalexin (plant antibiotic) by many diverse plant species including grapes, berries, peanuts as well as some species of pine trees, Acacias spp., Terminalias spp. (including T. sericea), orchids and lilies (Kopp 1998; Polunin et al. 2002; Joseph et al. 2007 ). The methanol extracts of the plant species displaying anti-Proteus activity were further analysed by RP-HPLC chromatography to determine whether they contain resveratrol. However, resveratrol itself did not show anti-Proteus activity at levels up to 1,000 lg/ml. Of the plant extracts tested, only the T. pruinoides (Fig. 3d) and T. sericea (Fig. 3e) extracts displayed peaks at the same elution volume as pure resveratrol (Fig. 3f) . The UV/Vis spectra showed that these peaks had spectral properties consistent with that of pure resveratrol (Fig. 3g) , with absorption maxima at approximately 216 and 303 nm. However, both the T. pruinoides and the T. sericea extracts contained only low levels of resveratrol. None of the other plant extracts gave chromatograms or had UV/Vis spectral properties indicative of resveratrol.
Discussion
Plant remedies are becoming increasingly sought after in the treatment of a myriad of diseases and disorders due both to their perception of greater safety than many synthetic drugs, and the failure of current drug regimes to effectively treat many diseases. This is especially true for rheumatoid arthritis. The current treatments utilising DMARDs to alleviate the symptoms of RA and/or alter the disease progression are not entirely effective and have been associated with numerous adverse effects (Alataha et al. 2003) . Furthermore, many of the current treatments are aimed at treating the symptoms of RA without addressing the underlying causes and pathogenic mechanisms. A better understanding of the mechanisms for initiation and progression of RA is important for developing new drugs to target-specific processes and thus more effectively treat RA (Whitehouse et al. 2013) .
Although the etiology of RA is not completely understood, the role of Proteus spp. (especially P. mirabilis) infection as a trigger of RA is now widely accepted due to a wealth of supporting evidence (as reviewed by Ebringer and Rashid 2006) . A treatment regime targeting the microbial trigger of RA is an attractive prospect as it would be expected to block/decrease production of self-reactive antibodies linked to disease onset and progression. The results presented here demonstrate the ability of a variety of plants which are used traditionally to treat RA and inflammatory complaints in Southern Africa to inhibit P. mirabilis and P. vulgaris growth when tested in the form that they would have been used in traditional medicine, i.e. teas (aqueous extracts), decoctions and tinctures. Further quantification by MIC determination demonstrated the efficacy of these extracts as inhibitors of the possible microbial trigger of RA. L. javanica leaf, S. cordatum bark and leaf, T. pruinoides leaf and T. sericea leaf extracts were of particular interest, with MIC's as low as 49 lg/ml. Indeed, these plant extracts proved to be substantially stronger than the control antibiotics (ampicillin and chloramphenicol) and are thus worthy of further phytochemical and mechanistic studies. The current study was limited to the inhibitory activity towards a microbial trigger of RA. Many of the plant extracts studied here may also have affects on other inflammatory processes (e.g. cytokine release) and, therefore, may help control RA by pluripotent/multifaceted mechanisms.
Herbal remedies have long been used to alleviate rheumatic complaints in all traditional medicine systems. In many cases, the major anti-inflammatory components of these plants are available in a pure form and already available as anti-inflammatory agents. These compounds include a variety of polyphenolic compounds, of which 3,5,4 0 -trihydroxy-trans-stilbene (resveratrol) has received much recent attention due to its presence in many plants used in the treatment of inflammation, and due to its potent anti-rheumatoid activity (Elmali et al. 2007; Wang et al. 2006) . Most studies examining the role of resveratrol in the treatment of RA focus on its ability to act as a potentspecific inhibitor of NF-jB activating as an inducer for two major inflammatory cytokines, TFN-a and IL-1b (Elmali et al. 2007 ). Thus, resveratrol treatment is known to block cytokine production and inflammation via its inhibition of NF-jB activation. It is possible that resveratrol may also have other anti-rheumatic effects as it also has known antibacterial activity against a variety of bacterial species (Paulo et al. 2010) . Of the plant extracts examined in this study, only the Terminalia species (T. pruinoides and T. sericea) contained resveratrol, and then only at comparatively low levels.
However, resveratrol did not inhibit the growth of either P. mirabilis or P. vulgaris in our test systems, even at concentrations up to 1,000 lg/ml. Furthermore, we were unable to find any reports of its in vitro anti-Proteus growth inhibition. Resveratrol is reported to inhibit P. mirabilis swarming and virulence factor expression in vivo, so it may affect P. mirabilis colonisation and infection within the urinary tract (Wang et al. 2006 ) but through mechanisms other than growth inhibition or bactericidal mechanisms. Any extracts inhibiting Proteus spp. growth that also contained resveratrol could express anti-RA activity via several mechanisms (growth inhibition, colonisation blocking, cytokine production inhibition) and might be particularly interesting for the treatment of RA. Further studies are required to determine if the levels of resveratrol present in the Terminalia spp. examined in this study would be sufficient to inhibit swarming and cytokine production.
The absence of resveratrol in the other plant species which demonstrated anti-Proteus activity confirms that the growth inhibitory activity seen for these extracts was induced by different phytochemical components. Compounds from other phytochemical classes including alkaloids, anthraquionones, flavonoids, polyphenolics, phytosterols, saponins, tannins and terpenes have also been linked with anti-bacterial activity in different plant species and thus may be responsible (at least in part) for the antiProteus activities reported here. The terpenes isomenthone and diosphenol as found in A. betulina are well known for their antimicrobial and urinary tract disinfectant properties (van Wyk et al. 2009 ). S. cordatum extracts have been shown to contain pentacyclic triterpenoids, phytosterols, proanthocyanidins and tannins (van Wyk et al. 2009 ), any of which could be responsible for antimicrobial and antiinflammatory properties. Terminalia spp. and W. salutaris are also high in sesquiterpenoids (including polygoidal) and tannins which also have reported antibacterial properties (van Wyk et al. 2009 ). Similarly, the volatile oils from L. javanica and Pellargonium spp. are rich in monoterpenoids with strong antibacterial and anti-inflammatory properties (van Wyk et al. 2009 ). Furthermore, the oils from Pellargonium spp. have also been reported to be rich in sesquiterpenes and alkaloids,. The terpenoid and saponin extracts of P. viridiflorum are thought to have both antimicrobial and anti-inflammatory activity (van Wyk et al. 2009 ). Several C. edulis and K. africana flavonoids have documented antimicrobial activity (van Wyk et al. 2009 ). Further bioactivity-guided separation studies are recommended to identify the anti-Proteus compounds in these plant extracts.
The findings reported here also demonstrate that none of plant extracts tested displayed significant toxicity in the Artemia nauplii bioassay. Indeed, of the extracts tested, only the P. fasiculata leaf water extract, and the T. violaceae root and leaf water extracts induced mortality significantly above that of the negative control. Determination of the LC 50 values indicated that only T. violaceae extracts displayed LC 50 values below 1,000 lg/ml. Therefore, all other plant extracts are defined as non-toxic as compounds with an LC 50 of greater than 1,000 lg/ml towards Artemia nauplii have been previously defined as being non-toxic (Meyer et al. 1982) . Even the T. violaceae extracts which did not show significant anti-Proteus activity (with LC 50 values [700 lg/ml) are considered of only low toxicity. It was, therefore, determined that all extracts tested here were either non-toxic or of low toxicity.
Conclusions
The antimicrobial efficacies of this study against the antiinflammatory marker Proteus spp. partially validate the usage of these particular plants in traditional South African medicinal systems to treat RA and other inflammatory conditions. They also indicate that the phytochemistry and pharmacology of these plants are worthy of further study, particularly for any other activities associated with the treatment of RA (e.g. inhibition of cytokine production). Whilst the extracts examined in this report are promising as anti-RA agents, caution is needed before these extracts can be applied to medicinal purposes. In particular, further toxicity studies using human cell lines are needed to verify the suitability of these extracts for further clinical studies.
